@article{f11eea589ba44b52ae2cbb9a525fabec,
title = "Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States",
abstract = "Background: Cystic fibrosis (CF) patients from Canada have better-reported post–lung transplant survival compared to patients from the United States. We hypothesized the clinical characteristics of CF patients prior to lung transplant differ between the two countries. Methods: Population-based cohort study utilizing combined Canadian CF Registry and US CF Foundation Patient Registry data from 1986 to 2013. Demographic and clinical variables were analyzed prior to lung transplant. Results: Between 1986 and 2013, 607 (10.2%) CF patients underwent lung transplantation in Canada and 3428 (7.5%) in the United States. A lower proportion of recipients had growth of B. cepacia complex prior to transplant in the United States compared to Canada (0.8% vs 4.3%). Lung function was similar between recipients from the two countries. The proportion of patients classified as underweight was significantly higher in the United States compared to Canada (39.8% vs 28.0%; SD 26.1) despite higher rates of feeding tube use (42.5% vs 28.6%; SD 29.0). Conclusions: CF lung transplant recipients from the United States have similar lung function, lower rates of B. cepacia complex, and worse nutritional parameters prior to transplant compared to counterparts in Canada. Future studies are necessary to evaluate the impact of these differences on post-transplant survival.",
keywords = "epidemiology, patient characteristics, registry, registry analysis",
author = "Quon, {Bradley S.} and Jenna Sykes and Sanja Stanojevic and Marshall, {Bruce C.} and Kristofer Petren and Josh Ostrenga and Aliza Fink and Alexander Elbert and Albert Faro and Goss, {Christopher H.} and Stephenson, {Anne L.}",
note = "Funding Information: Dr. Quon reports salary awards from Cystic Fibrosis Canada and the Michael Smith Foundation for Health Research; grants from Cystic Fibrosis Canada, the Cystic Fibrosis Foundation, and British Columbia Lung Association; and honorarium from Proteostasis Therapeutics, Inc. Dr. Goss reports board membership at KaloBios Pharmaceuticals and Boehringer Ingelheim; consultancy for Vertex Pharmaceuticals and Novartis; grants from Vertex Pharmaceuticals, the Cystic Fibrosis Foundation, the National Institutes of Health, and the US Food and Drug Administration; speaking fees from Hoffmann-La Roche, Johns Hopkins University, the European Cystic Fibrosis Society, and Medscape; and an honorarium from Gilead Sciences. Dr. Stephenson reports grants from the Cystic Fibrosis Foundation during the conduct of the study and personal fees from Cystic Fibrosis Canada outside the submitted work. Ms. Sykes reports grants from the Cystic Fibrosis Foundation during the conduct of the study. The authors not named here have disclosed no conflict of interest. Funding Information: We would like to acknowledge the support of the US CFF and Cystic Fibrosis Canada, which made this study possible. In addition, we would like to acknowledge and thank all of the CF patients and families in the USA and Canada who consent to be part of their respective Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2018",
month = mar,
doi = "10.1111/ctr.13188",
language = "English (US)",
volume = "32",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",
}